Spontaneous Non-Traumatic Stress Fractures in Bilateral Femoral Shafts in a Patient Treated with Bisphosphonates |
Shin, Dong-Yeob
(Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine)
Ku, Cheol-Ryong (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) Kim, Kyung-Min (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) Choi, Han-Seok (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) Rhee, Yu-Mie (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) Lee, Eun-Jig (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) Lim, Sung-Kil (Department of Internal Medicine and Endocrine Research Institute, Yonsei University College of Medicine) |
1 | Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761. DOI ScienceOn |
2 | Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. DOI |
3 | Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006;61:31-33. |
4 | Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for highturnover osteoporosis. N Engl J Med 2006;355:2048-2050. |
5 | Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage ccumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23 Suppl:36-42. |
6 | Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002;43:535-537. DOI |
7 | Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-307. DOI ScienceOn |
8 | Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-1480. DOI ScienceOn |
9 | Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial. Ann Intern Med 1999;131:935-942. |
10 | Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938. DOI |